FDA declines to approve Orexigen diet drug

Feb 01, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Orexigen Therapeutics Inc. shares plunged nearly 75 percent in pre-market trading Tuesday after U.S. health officials declined to approve the experimental weight loss pill Contrave.

The said it wants the company to conduct an additional study to address potential heart safety issues. The FDA request suggests the agency may yet approve the drug, but makes that path more difficult.

Orexigen said it is disappointed with the FDA's decision and will work with the agency to determine its next step.

Analysts have viewed Contrave as the most promising of three new recently submitted to the agency. Contrave is a combination pill, mixing an antidepressant with an anti-addiction drug to curb appetite. Four out of 10 patients taking Contrave for a year lost at least 5 percent of their body weight. Those results narrowly met FDA's guidelines for effectiveness.

La Jolla, Calif.-based Orexigen does not currently have any products on the market, making Contrave a key to the company's growth and survival. In pre-market trading Tuesday, Orexigen shares tumbled $6.67, or 73 percent, to $2.42.

Analysts expect any obesity drug reaching the market to have the potential to become a billion-dollar seller.

With the U.S. obesity rate for adults nearing 35 percent, the FDA has acknowledged the need for new weight loss drugs. But the agency rejected two other drugs last year due to safety risks, a long-standing issue that has plagued weight loss treatments for decades. Those drugs were made by fellow California drug developers Vivus Inc. and Arena Pharmaceuticals Inc. Both companies have said they plan to resubmit their drugs for approval.

Contrave has been pegged as a more promising treatment because of its relative safety. Unlike the other two drugs reviewed last year, it received a positive vote from the FDA's panel of outside advisers, who voted 13-7 that the drug's modest weight loss benefits outweighed its risks.

But the FDA meeting assessing the drug was not free of criticism. FDA scientists and safety advocates complained that the company enrolled few elderly patients or patients with a history of heart disease in its trials, making it difficult to determine the drug's safety in patients who are likely to need it most.

Heart side effects have been an issue with diet drugs, most notably with Wyeth's diet drug combination fen-phen, which was pulled off the market in 1997. In October, Abbott Laboratories withdrew its drug Meridia after evidence it increased the risk of heart attack and stroke.

Currently there is just one prescription drug on the market for long-term weight loss: Roche's Xenical, which is not widely used. Several other generic drugs are approved for short-term , including phentermine.

Explore further: More than a quarter of emergency contraceptives in Peru falsified or substandard

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA scrutinizes weight loss pill from Orexigen

Dec 03, 2010

(AP) -- Scientists for the Food and Drug Administration said Friday a pill to treat obesity from Orexigen Therapeutics Inc. helped patients lose weight, though it didn't meet all the criteria set forth by the agency.

FDA panel recommends approval for Contrave

Dec 08, 2010

A Food and Drug Administration panel on Tuesday recommended that the agency approve Orexigen Therapeutics Inc.'s weight loss drug Contrave, making it the first in group of competitors to get a positive nod from experts.

FDA panel rejects experimental weight loss pill

Jul 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

Vivus weight loss drug faces FDA panel this week

Jul 13, 2010

(AP) -- Vivus Inc.'s experimental drug Qnexa was effective in cutting weight, the Food and Drug Administration said Tuesday, while acknowledging lingering concerns over the drug's nervous system and psychiatric side effects.

FDA rejects highly-anticipated diet drug Qnexa

Oct 29, 2010

(AP) -- Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.

FDA to review first of 3 new weight loss drugs

Jul 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

gwrede
not rated yet Feb 01, 2011
Eating less doesn't seem to be an option...

More news stories

Treating depression in Parkinson's patients

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.

Health care site flagged in Heartbleed review

People with accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the ...